2oxo-PCP

The following information was compiled in February 2026 and is subject to change as new research is conducted and as new information becomes available:

Description: 2oxo-PCP is a novel hallucinogen characterized as an arylcyclohexylamine and bears structural similarity to other phencyclidine (PCP) and eticyclidine (PCE) analogues (e.g., 3Me-PCP, 3MeO-PCP, 2oxo-PCE). No pharmacology data is currently available for 2oxo-PCP; however, it is hypothesized to be a potent N-methyl-D-aspartate (NMDA) receptor antagonist.^1,2 2oxo-PCP has been detected in one postmortem blood specimen to date at the CFSRE. The toxicology specimen originated from Illinois and 2oxo-PCP was found alongside methiodone (also known as IC-26) and N-piperidinyl methiodone (also known as DPP-26). 2oxo-PCP has not been detected in any drug materials to date at the CFSRE. 2oxo-PCP was identified by our laboratory in August 2025 and confirmed in March 2026 after acquiring standard reference material. 2oxo-PCP is not currently scheduled in the United States.

Class:

Hallucinogen

Appearance:

Blood

Formula:

C17H23NO

MW:

257.4

[M+]:

257

[M+H]+:

258.1852

IUPAC:

2-phenyl-2-(1-piperidinyl)-cyclohexanone

Report Date:

February 12, 2026